In clinical studies exploring pembrolizumab, an inhibitor of the immunosuppressive protein programmed cell death protein 1 (PD-1), as a treatment for PML, an increased JCPyV-specific CD8+ T cell response was linked with lower viral loads and, ultimately, clinical improvement [3]. The gene discussed is CD8A; the disease is progressive multifocal leukoencephalopathy.